TARA: protaratx.com Price/Earnings to Growth Multiple
The development of the TARA-002 drug for the therapy of bladder cancer and lymphatic pathologies drives current progress for Protara Therapeutics (TARA). The P/E to growth rate dynamics correlate with these milestones, where the value of 0.00 reflects this status. Global sales of unique medications ensure high margins, while the strategic allocation of active substance inventories guarantees supply stability without logistical disruptions.
Metric breakdowns and analytics for Protara Therapeutics (TARA)
- share price and consensus valuation forecast:
- market capitalization information:
- book value of equity indicators:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
TARA - Net Profit|Projected Future Earnings Protara Therapeutics|TARA - Price to Earnings Ratio|Future Price to Earnings Multiple Protara Tx|TARA - PEG Multiple|EV/EBITDA Multiple Protara|TARA - Operating profit before deduction of amortization|Earnings per share for the trailing year Protara Therapeutics|TARA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months protaratx.com|TARA - Earnings growth in current year|Expected earnings per share trend next year Protara Therapeutics
Fundamental company analysis:Protara Therapeutics Inc, TARA
Protara Therapeutics (TARA) specializes in developing high-tech therapies for rare oncological diseases, which requires significant R&D investment. This PEG ratio compares the current P/E to earnings growth, allowing investors to determine the cost of each percentage of business expansion; a metric drop below one signals that the capital is undervalued relative to the growth prospects of the biopharmaceutical brand.
Competitors of Protara Therapeutics
ONC (BeiGene Ltd.) - Growth-Adjusted Payback Ratio|PEG Multiple HALO (Halozyme Inc.)|RVMD - Price/Earnings to Growth Multiple|AAPG: Price/Earnings to Growth Multiple|CGON - PEG Multiple|UroGen Pharma (URGN) - Price/Earnings to Growth Ratio|Bicara Therapeutics Inc - Growth-Adjusted Payback Ratio|PSNL (Personalis Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Erasca Oncology ERAS|Price/Earnings to Growth Ratio Delcath Systems, Inc. (DCTH)|YMAB: Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Ratio Aura Biosciences AURA|Growth-Adjusted Payback Ratio CADL|ARAY - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate SELLAS Life Sciences|ACTU (Actuate Therapeutics, Inc.) - Price/Earnings to Growth Multiple|CTOR: Company Value to Earnings Growth Ratio|HURA (TuHURA Biosciences Inc.) - PEG Multiple|PEG Multiple Fate Therapeutics Inc|Price/Earnings to Growth Ratio Aadi Bioscience Inc (WHWK)|TCRX (tscan.com) - Growth-Adjusted Payback Ratio|PEG Multiple CSBR (Champions Oncology, Inc.)|PEG Multiple XBiotech Inc XBIT|CVM: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio OSTX (OS Therapies Inc.)|RADX (Radiopharm Theranostics Limited) - Price/Earnings to Growth Multiple|ARTV: Company Value to Earnings Growth Ratio|ANL (Adlai Nortye Ltd) - PEG Multiple|VERU: Growth-Adjusted Payback Ratio|PEG Multiple TPST|XLO - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Renovaro RENB|Growth-Adjusted Payback Ratio MURA|Kairos Pharma Inc - PEG Multiple|OKUR - PEG Multiple|w2.cytomed.sg (GDTC) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio CRIS (Curis)|APLM (Apollomics Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Tharimmune Corporation THAR|Price/Earnings to Growth Multiple ADVB (Advanced Biomed Inc)|PEG Multiple genprex.com (GNPX)|Calidi Biotherapeutics, Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio SBFM (Sunshine Biopharma Inc.)|Xenetic Bio - PEG Multiple|Growth-Adjusted Market Cap to Net Income Salarius Pharma SLRX|PPBT: PEG Multiple|Price/Earnings to Growth Multiple American Oncology Network, Inc.|Price/Earnings to Growth Ratio BeiGene|Checkpoint Therapeutics Inc. (CKPT) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple ELEV (Elevation Oncology, Inc.)|Company Value to Earnings Growth Ratio ICAD|PEG Multiple IKNA (Ikena Oncology)|PEG Multiple notablelabs.com NTBL|VIRX - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio MOR (MorphoSys Inc)|NAYA: PEG Multiple|Ascentage (AAPGV) - PEG Multiple
